Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
The real value comes from medical oversight, clear pricing, personalized medication guidance, and a provider who stays involved after the first prescription
In an inactive state, ECD favors a closed conformation covering the TMD
According to recently published clinical research by Galderma in January 2025, patients using GLP-1 medications frequently report significant facial alterations: Loss of facial volume creating shadowing and hollowness Increased skin laxity and sagging Changes in facial structure and balance Skin appearing less radiant and drier An overall aged appearance beyond their chronological age Dr
Liraglutide-induced injection site reaction
hs-CRP and inflammation hs-CRP is a marker of low-grade inflammation
